{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:53:12Z","timestamp":1792183992058,"version":"4.4.0"},"reference-count":44,"publisher":"Hindawi Limited","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2909,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01515.x","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T15:57:54Z","timestamp":1186675074000},"page":"1739-1748","source":"Crossref","is-referenced-by-count":15,"title":["Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician role"],"prefix":"10.1155","volume":"61","author":[{"given":"H. S.","family":"Kirshner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2007,9,14]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/01.STR.0000199147.30016.74","article-title":"Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association\/American Stroke Association Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline","volume":"37","author":"Sacco","year":"2006","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1212\/01.WNL.0000110311.09970.83","article-title":"Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies","volume":"62","author":"Lovett","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.54.5.1022","article-title":"Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients","volume":"54","author":"Albers","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.STR.0000116183.50167.D9","article-title":"Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study","volume":"35","author":"Hardie","year":"2004","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/hs0402.105246","article-title":"Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease","volume":"33","author":"Vickrey","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)66702-5","article-title":"A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack","volume":"366","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1503\/cmaj.1030460","article-title":"Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. North American Symptomatic Carotid Endarterectomy Trial Group","volume":"170","author":"Eliasziw","year":"2004","journal-title":"CMAJ"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.74.5.577","article-title":"Long term risks of stroke, myocardial infarction, and vascular death in \u2018low risk\u2019 patients with a non-recent transient ischaemic attack","volume":"74","author":"Clark","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1001\/jama.284.22.2901","article-title":"Short-term prognosis after emergency department diagnosis of TIA","volume":"284","author":"Johnston","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB10|cit10","volume-title":"Patient Flow Analysis of Stroke\/TIA Patients","author":"Copernicus: The Marketing Investment Strategy Group","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/01.STR.0000028456.18614.93","article-title":"Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association)","volume":"33","author":"Coull","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anticoagulants vs. aspirin after cerebral ischemia of presumed arterial origin","volume":"42","author":"Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1474-4422(06)70685-8","article-title":"Medium intensity oral anticoagulants vs. aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial","volume":"6","author":"Algra","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin vs. oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ACTIVE Writing Group on behalf of the ACTIVE Investigators","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial","volume":"289","author":"Gorelick","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Patrono","year":"2004","journal-title":"Chest"},{"issue":"3 Suppl","key":"10.1111\/j.1742-1241.2007.01515.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"483S","DOI":"10.1378\/chest.126.3_suppl.483S","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Albers","year":"2004","journal-title":"Chest"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2007.01515.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s10072-004-0209-4","article-title":"New therapeutic strategies with antiplatelet agents","volume":"25","author":"Micieli","year":"2004","journal-title":"Neurol Sci"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11936-006-0015-9","article-title":"The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke","volume":"8","author":"Booze","year":"2006","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.STR.19.4.512","article-title":"Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke","volume":"19","author":"Dutch TIA Study Group","year":"1988","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results","volume":"54","author":"Farrell","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.STR.0000110221.54366.49","article-title":"Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events Investigators","volume":"35","author":"Ringleb","year":"2004","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin vs. aspirin alone for the prevention of atherothrombotic events. CHARISMA Investigators","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/archneur.62.3.403","article-title":"Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations","volume":"62","author":"Sacco","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole vs. aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial","volume":"367","author":"ESPRIT Study Group","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jnnp.66.5.557","article-title":"Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone","volume":"66","author":"Algra","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0149-2918(00)80041-7","article-title":"Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis","volume":"22","author":"Shah","year":"2000","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1592\/phco.21.5.452.34498","article-title":"Antithrombotic drugs for secondary stroke prophylaxis","volume":"21","author":"Pettigrew","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB38|cit38","article-title":"Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events","author":"National Institute for Health and Clinical Excellence","journal-title":"NICE Technology appraisal guidance 90"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.20942","article-title":"National Stroke Association Guidelines for the management of transient ischemic attacks","volume":"60","author":"Johnston","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3122\/jabfm.18.6.528","article-title":"Long-term therapy to prevent stroke","volume":"18","author":"Kirshner","year":"2005","journal-title":"J Am Board Fam Pract"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel vs. aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.10451","article-title":"Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials","volume":"75","author":"Serebruany","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1742-1241.2007.01515.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000100105","article-title":"Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan vs. placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS)","volume":"23","author":"Diener","year":"2007","journal-title":"Cerebrovasc Dis"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01515.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01515.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:09Z","timestamp":1643349909000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01515.x"}},"subtitle":["Secondary stroke prevention"],"short-title":[],"issued":{"date-parts":[[2007,9,14]]},"references-count":44,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01515.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9,14]]}}}